3 completed, 1 terminated. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Sarcoma, Soft Tissue: new trials by email Literature Review of Sarcoma, Soft Tissue trials Research Report on Sarcoma, Soft Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trabectedin Maintenance Post 1st-line in STS Trabectedin - Sarcoma, Soft Tissue | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 13 | 2017-11-07 | 2020-09-02 |
| Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy PAZOPANIB, Placebo - Sarcoma, Soft Tissue | Phase 3 | Completed | GlaxoSmithKline | 369 | 2008-10-01 | 2013-08-22 |
| Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Laboratory Assay, Mick Assay - Breast Neoplasms, Lung Neoplasms | Phase 2 / Phase 3 | Completed | Pierian Biosciences | 150 | 2006-09-01 | 2012-01-26 |
| Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Gemcitabine, Docetaxel - Sarcoma, Soft Tissue | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 120 | 2003-01-01 | 2007-10-02 |
Sarcoma (4) · Breast Neoplasms (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Adnexal Diseases (1) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Lung Diseases (1) · Neoplasms by Site (1)
Docetaxel (1) · Drug Therapy (1) · Gemcitabine (1) · Trabectedin (1) · pazopanib (1)
European Organisation for Research and Treatment of Cancer - EORTC (1) · GlaxoSmithKline (1) · Memorial Sloan Kettering Cancer Center (1) · Pierian Biosciences (1)
United States (3) · France (2) · Germany (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Denmark (1) · Italy (1) · Japan (1) · Poland (1) · South Korea (1) · Sweden (1)
Alexander Zweibach, MD, PhD (1) · Cary Presant, MD (1) · Hans Gelderblom (1) · Karl Rogers, MD (1) · Pat Whitworth, MD (1) · Robert Maki, MD, PhD (1)
PMID 24504442, PMID 26864131, PMID 31409302
2016 (1)